Levosimendan and nesiritide as a combination therapy in patients with acute heart failure

American Journal of the Medical Sciences

Volumn 349, Issue 5, 2015, Pages 398-405

  Jia, Zhi ^a   Guo, Mu ^a   Zhang, Li Yuan ^a   Zhang, Yun Qiang ^a   Liang, Hai Qing ^a   Song, Yu ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Heart failure; Levosimendan; Nesiritide; Ventricular function

Indexed keywords

DOBUTAMINE; DOPAMINE; LANATOSIDE C; LEVOSIMENDAN; NESIRITIDE; PLACEBO; BRAIN NATRIURETIC PEPTIDE; CARDIOTONIC AGENT; HYDRAZONE DERIVATIVE; PYRIDAZINE DERIVATIVE; SIMENDAN;

ACUTE HEART FAILURE; AGED; ARTICLE; CLINICAL EFFECTIVENESS; CONTINUOUS INFUSION; CONTROLLED STUDY; CORONARY CARE UNIT; DRUG EFFICACY; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; HYPOTENSION; INTRAAORTIC BALLOON PUMP; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME; ACUTE DISEASE; DRUG COMBINATION; DRUG MONITORING; DRUG POTENTIATION; HEART FAILURE; HOSPITAL READMISSION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; VERY ELDERLY;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; CARDIOTONIC AGENTS; DRUG MONITORING; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HEART FAILURE; HUMANS; HYDRAZONES; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MORTALITY; NATRIURETIC PEPTIDE, BRAIN; PATIENT READMISSION; PYRIDAZINES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84928966715     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0000000000000461     Document Type: Article

References (21)

1. Holtwick R, van Eickels M, Skryabin BV, et al. Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. J Clin Invest 2003;111:1399-407.
2. Michaels AD, Klein A, Madden JA, et al. Effects of intravenous nesiritide on human coronary vasomotor regulation and myocardial oxygen uptake. Circulation 2003;107:2697-701.
3. Lainchbury JG, Burnett JC Jr, Meyer D, et al. Effects of natriuretic peptides on load and myocardial function in normal and heart failure dogs. Am J Physiol Heart Circ Physiol 2000;278:H33-H40.
4. Holmes SJ, Espiner EA, Richards AM, et al. Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. J Clin Endocr Metab 1993;76:91-6.
5. Gassanov N, Biesenbach E, Caglayan E. Natriuretic peptides in therapy for decompensated heart failure. Eur J Clin Pharmacol 2012;68:223-30.
6. Mullens W, Abrahams Z, Francis GS. Sodium nitroprusside for advanced low-output heart failure. J Am Coll Cardiol 2008;52:200-7.
7. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;62:e147-239.
8. Lindenfeld J, Albert NM, Boehmer JP, et al. HFSA 2010 comprehensive heart failure practice guideline. J Card Fail 2010;16:e1-194.
9. Kristof E, Szigeti G, Papp Z, et al. Cardiac responses to calcium sensitizers and isoproterenol in intact guinea pig hearts. Effects on cyclic AMP levels, protein phosphorylation, myoplasmic calcium concentration and left ventricular function. Ann N Y Acad Sci 1998;853: 316-9.
10. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008;29:2388-442.
11. O'Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011; 365:32-43.
12. Landoni G, Mizzi A, Biondi-Zoccai G, et al. Levosimendan reduces mortality in critically ill patients. A meta-analysis of randomized controlled studies. Minerva Anestesiol 2010;76:276-86.
13. Landoni G, Biondi-Zoccai G, Greco M, et al. Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies. Crit Care Med 2012;40:634-46.
14. Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 2007;297:1883-91.
15. Bergh CH, Andersson B, Dahlstrom U, et al. Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers. Eur J Heart Fail 2010;12:404-10.
16. Duman D, Palit F, Simsek E, et al. Effects of levosimendan versus dobutamine on left atrial function in decompensated heart failure. Can J Cardiol 2009;25:e353-6.
17. Berger R, Moertl D, Huelsmann M, et al. Levosimendan and prostaglandin E1 for uptitration of beta-blockade in patients with refractory advanced chronic heart failure. Eur J Heart Fail 2007;9:202-8.
18. Miller WL, Hartman KA, Burritt MF, et al. Biomarker responses during and after treatment with nesiritide infusion in patients with decompensated chronic heart failure. Clin Chem 2005;51:569-77.
19. Fitzgerald RL, Cremo R, Gardetto N, et al. Effect of nesiritide in combination with standard therapy on serum concentrations of natriuretic peptides in patients admitted for decompensated congestive heart failure. Am Heart J 2005;150:471-7.
20. Jia Z, Guo M, Zhang YQ, et al. Efficacy of intravenous levosimendan in patients with heart failure complicated by acute myocardial infarction. Cardiology 2014;128:195-201.
21. Silva-Cardoso J, Ferreira J, Oliveira-Soares A, et al. Effectiveness and safety of levosimendan in clinical practice. Rev Port Cardiol 2009;28:143-54.